PHONE
+44-7482-878921
+44-7482-878921
2376-0249
Clinical-Medical Image - International Journal of Clinical & Medical Images (2024) Volume 11, Issue 6
Author(s): Amellouk Sara*, Bennani Hakim, Bensmimou Hafsa, Batani Halima, Oussafrar Zakaria and Guensi Amal
Department of Nuclear Medicine, University Hospital Center Ibn Rochd, Casablanca, Morocco
Received: 31 May 2024, Manuscript No. ijcmi-24-137767; Editor assigned: 03 June 2024, Pre QC No. P-137767; Reviewed: 14 June 2024, QC No. Q- 137767; Revised: 19 June 2024, Manuscript No. R-137767; Published: 26 June 2024, DOI:10.4172/2376-0249.1000961
Citation: Sara A, Hakim B, Hafsa B, Halima B and Zakaria O, et al. (2024) Contribution of 18F-PSMA PET/CT to the Extension Workup of Intermediate-Risk Prostatic ADK: A Case Report. Int J Clin Med Imaging 11: 961.
Copyright: © 2024 Sara A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PSMA PET/CT (Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography) has emerged as a significant tool in both the primary diagnosis and management of Prostate Cancer (PCa) recurrence. Studies have shown that the Gleason score and PSA level was correlated with the intensity of tracer accumulation in the primary tumors of prostate cancer patients on 18F-PSMA PET/CT1. The aim of the study was to evaluate the potential utility of 18F-PSMA PET/CT imaging in diagnosing patients with an intermediate risk of prostate cancer.
PSMA PET/CT, Prostate cancer, Intermediate risk
Nil.
There are no conflicts of interest.
[1] Uprimny C, Kroiss AS, Decristoforo C, Fritz J and von Guggenberg E, et al. (2017). 68 Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 44: 941-949.
Google Scholar, Crossref, Indexed at
[2] Hong JJ, Liu BL, Wang ZQ, Tang K and Ji XW, et al. (2020). The value of 18 F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer. EJNMMI Res 10: 1-8.
Google Scholar, Crossref, Indexed at
[3] Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H and Yaxley WJ, et al. (2019). Risk of metastatic disease on 68gallium‐prostate‐specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int 124(3): 401-407.
Awards Nomination
